RE:RE:RE:RE:Financinglscfa wrote: https://www.prnewswire.com/news-releases/skinmedica-launches-even--correct-301721744.html#:~:text=SkinMedica%C2%AE%20Even%20%26%20Correct%20Dark,the%20look%20of%20dark%20spots.&text=SkinMedica%C2%AE%20Even%20%26%20Correct%20Brightening,and%20uneven%20tone%20and%20texture.
Pandora wrote: Turtle4 wrote: GPM is the only active ingredient that works really well. Everything else has failed or is selling badly (tfc1067). I would rather wait longer (smaller product launch and possible supply bottlenecks) than give away a high percentage. The big mistake was to hope for high sales of tfc1067 instead of securing funding for GPM with a high upfront or complete sale of the tfc1067 patents.
My humble opinion is that AbbVie(Allergen) is one of the larger distributers of a competitive product to TFC1067 and by getting the agreement with SBM for the distribution of 1067 they can curtail it's distribution point while making good money on it's existing product.
Who knows how long it may take for them to decide they need a new avenue by introducing TFC1067 and thus losing some income on their existing product.
Does anyone know the market well enough to point out a product or products that AbbVie currently is distributing in the "dark spots" category?
I just feel they have no thought of introducing a new TFC1067 to the market to in effect cut off a major revenue source they already have on an exisiting product. Moving TFC1067 into the market is likely dependant on how well they are doing with their existing product.
Don't know if that makes any sense but it's the only way I can rationalize why they would not be getting TFC1067 to the market i.e. they are already making a bundle off something else that will be curtailed by the introduction of TFC1067. A matter of balance of income for them at the expense of no introduction of the new product for us. How long has it been thus far??
So it looks like SkinMedica is an Allergan/Abbvie company with worldwide high selling products and to me, as I suggested, there is no need for AbbVie to introduce the TFC1067 product. It appears it is in their best interest to just keep it on the shelf and I don't think it is costing them a large amount to do that.
When making deals there is that old saying "I've been Snookered" which seemingly applies here to SBM management. They needed to find a company that would carry TFC1067 to the market as a competitor to SkinMedica by AbbVie. The way it ended is that AbbVie holds all the strings and TFC1067 sits on the shelf. And we, as shareholders, get essentially no returns. As they say, all is fair in love and war -- and this is a marketing war that appears to show us as a loser. Will it ever change? At this point that is a hard call but it does not look like a change in the near term.
Hopefully they are doing a much better job with the anti-aging. Once bitten, twice shy!